Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration.

What It Covers

Researchers studied Wolverine Blend (BPC-157 + TB-500) in this meta-analysis publication.

Inclusion criteria were published randomised prospective trials enrolling patients with oligometastatic (up to five metastases) prostate cancer, in which investigators recorded sufficient data to evaluate progression-free survival and overall survival.

Why It Was Studied

Oligometastatic disease represents the proximal end of a metastatic spectrum.

Philanthropic gift and National Cancer Institute.

Who the Included Studies Covered

PubMed tags the participants as men only.

The researchers conducted a systematic review and individual patient data meta-analysis.

The researchers systematically searched Embase, PubMed, CENTRAL, MEDLINE, and ClinicalTrials.gov to identify randomised trials of MDT enrolling patients with oligometastatic prostate cancer.

How the Review Was Done

This systematic review was conducted from database creation to Nov 3, 2023, and was updated on May 4, 2025.

Data appraisal was conducted using Covidence with two investigators (CT and ADS) performing independent screens.

Studies were evaluated using the Cochrane Collaboration's risk-of-bias assessment (version 2.0).

Individual patient data were provided by investigators.

Coprimary endpoints were progression-free survival and overall survival.

What Was Measured

Secondary endpoints were radiographic progression-free survival and castration resistance-free survival.

The primary analysis was conducted in the subset of studies in which patients were randomly assigned to MDT plus standard of care (SOC) versus SOC.

The subject headings attached to it are Prostatic Neoplasms, Standard of Care, Neoplasm Metastasis, Randomized Controlled Trials as Topic and Progression-Free Survival.

What This Means in Plain Language

This is a meta-analysis of Wolverine Blend (BPC-157 + TB-500).

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (The Lancet. Oncology), a journal based in England.

More context: the Wolverine Blend (BPC-157 + TB-500) compound page, all human trials.